Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01747213 · ClinicalTrials.gov registry record · Phase 1

Bisnorcymserine in Healthy Adult Volunteers

A Phase 1 study, sponsored by National Institute on Aging (NIA).

Completed
Registry status
Phase 1
Development phase
75
Enrollment target

NCT01747213 is a Phase 1 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 75 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01747213, a Phase 1 study, has completed, sponsored by National Institute on Aging (NIA).

COMPLETED
Registry status
Phase 1
Development phase
75 participants
Enrollment target

Study Summary

Background: \- Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people. It is caused by abnormal proteins in the brain that affect how neurons communicate with each other. Researchers are looking for drugs that can slow down the disease or treat its symptoms. One drug, called bisnorcymserine (BNC), may help improve brain function and symptoms in people with AD. BNC is designed to block a chemical that affects how neurons communicate with each other. Researchers want to see how BNC works in healthy older volunteers. Objectives: \- To look at how the body processes bisnorcymserine taken by mouth and how safe it is for healthy older volunteers. Eligibility: \- Healthy volunteers at least 55 years of age. Design: * Participants will be screened with a physical exam, medical history, and blood and urine tests. * Within 3 weeks from the screening visit, participants will come to the National Institute on Aging clinical unit for a 2-night stay. On the morning of the second day, they will take either a BNC capsule or a placebo. They will not know which tablet they are taking. * Blood samples will be collected frequently throughout the second and third days of the study visit. The last blood sample will be collected about 32 hours after taking the study capsule. Participants will have heart function tests and other exams during the visit. Once the tests are done, they will leave the clinical center. * Participants will have a final follow-up visit about 1 week after leaving the clinical center.

Interventions

  • OTHER Placebo
  • DRUG BNC

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2013-01-29
Est. Completion 2019-01-08
Phase Phase 1

Sponsor

National Institute on Aging (NIA)

131 total trials

What the Registry Record Tells You About NCT01747213

The ClinicalTrials.gov registry entry for NCT01747213 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01747213 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01747213 about?

NCT01747213 is a clinical study titled "Bisnorcymserine in Healthy Adult Volunteers". Background: \- Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people. It is caused by abnormal proteins in the brain that affect how neurons communicate with each other....

What is the current status of trial NCT01747213?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2013-01-29. Estimated completion is 2019-01-08.

What interventions are being tested in trial NCT01747213?

The interventions under investigation include: Placebo (OTHER), BNC (DRUG).

Who is sponsoring clinical trial NCT01747213?

This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.